Enhanced Liver Fibrosis (ELF™) Test Gauges Likelihood of Disease Progression; Expands Labcorp’s Testing Options for Nonalcoholic Fatty Liver Disease The ELF test provides a numeric score to people ...

The BMP8A Fibrosis Score (BFS) offers improved accuracy over existing noninvasive scoring systems for identifying advanced liver fibrosis in MASH patients. BFS eliminates grey-zone results, providing ...

Combining retina scanning with liver stiffness assessment offers a promising, efficient approach to identify advanced fibrosis and MASLD in type 2 diabetes patients. Study: Screening for advanced ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and hepatocellular carcinoma. While fibroblast growth factor 21 (FGF21) analogs have shown ...

Background: FibroTest (FT) is the most frequently used serum fibrosis marker and consists of an algorithm of five fibrosis markers (alfa2-macroglobulin, apolipoproteinA1, haptoglobin, GGT, bilirubin).

At present, transient elastography and the serum marker FibroTest are the most intensively evaluated non-invasive methods for the assessment of liver fibrosis. The results of the present study for ...

More than 100 million people in the United States suffer from metabolic dysfunction-associated steatotic liver disease (MASLD ...

Liver fibrosis is a progressive and potentially reversible condition that results from chronic liver damage, which can be caused by a variety of factors, including metabolic dysfunction-associated ...

A surprising discovery by UCLA Health researchers may rewrite our understanding of how liver disease progresses. While it's long been believed that inflammation drives the scarring known as fibrosis ...

Scientists have found that combining silybin with carvedilol works far better against liver fibrosis than either drug alone. The duo targets the root drivers of liver scarring, sharply reducing ...